GlassScriptPhysician profile
Mala Adele Freeman-Kwaku
NPI 1972582286
$9,434.73
in general payments reported to CMS, 2019-2025
32 companies · $3,684 in 2025
The $3,684 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $106 · 2021: $271 · 2022: $1,462 · 2023: $1,449 · 2024: $1,790 · 2025: $3,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,704 · Food and Beverage: $3,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,704.00 |
| Food and Beverage | $3,219.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $4,005.70 | 2023-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Abbvie INC. | $930.97 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $717.51 | 2022-2025 | Nextstellis, Annovera |
| Astellas Pharma US INC | $670.96 | 2022-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $654.81 | 2019-2024 | |
| Organon LLC | $290.94 | 2021-2025 | Nexplanon |
| Janssen Pharmaceuticals, INC | $215.33 | 2020-2022 | |
| Exeltis, USA INC. | $192.51 | 2022-2025 | Slynd |
| Pfizer INC. | $185.37 | 2019-2024 | |
| Channel Medsystems, INC. | $172.23 | 2024-2025 | |
| Shield Therapeutics INC | $140.03 | 2023-2025 | Accrufer |
| Avion Pharmaceuticals | $135.95 | 2022-2023 | Balcoltra |
| Aspira Women'S Health INC | $125.75 | 2021-2023 | Ova1 |
| Idorsia Pharmaceuticals US INC | $121.78 | 2023 | Quviviq |
| Lupin INC. | $99.29 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $98.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $90.07 | 2025 | Airsupra |
| Daiichi Sankyo INC. | $82.50 | 2019 | |
| Millicent US INC | $76.61 | 2025 | Femlyv, Intrarosa, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $48.67 | 2022-2023 | |
| Mycovia Pharmaceuticals, INC. | $44.98 | 2022-2023 | Vivjoa |
| Hologic Sales and Service, LLC | $43.46 | 2021-2025 | Myosure Tissue Removal Device |
| Therapeuticsmd, INC. | $42.34 | 2019 | |
| Merck Sharp & Dohme LLC | $42.07 | 2022-2023 | Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $35.62 | 2023 | Seglentis |
| Coopersurgical, INC. | $33.53 | 2023-2024 | Paragard T 380a, Endosee |
| Amag Pharmaceuticals, INC. | $32.35 | 2019 | |
| Scynexis, INC. | $25.48 | 2022 | |
| Agile Therapeutics, INC. | $23.06 | 2022 | |
| Mission Pharmacal Company | $22.82 | 2019 | |
| Evofem Biosciences, INC. | $21.75 | 2021 | |
| Allergan, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mala Freeman-Kwaku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.